WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices. The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading. Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court. |
Countess exHairy Biker Dave Myers left wife Liliana £1.4m it's revealedOur £600,000 newPrince Louis wore Prince George's £25 handElection 2024: Puerto Rico Republicans award Trump all 23 delegatesThe body types that raise the risk of colon cancerVeteran DEA agent sentenced to 4 years for leaking intelligence in Miami bribery conspiracyA portrait by Gustav Klimt has been sold for $32 million at an auction in ViennaYokohama reaches Asian Champions League final by beating Ulsan in penalty shootout 5Pilot reported fire onboard plane carrying fuel, attempted to return to Fairbanks just before crash